Assignee
METACRINE INC
US·9 granted patents·15 pending applications·19 citations·filing 2016–2022
Top patents by PatentIndex Score
24 records- 0191US10626081B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2016·Granted Apr 21, 2020·4 cites·18 claims
- 0289US10377717B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2016·Granted Aug 13, 2019·3 cites·18 claims
- 0387US11773094B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2021·Granted Oct 3, 2023·1 cites·19 claims
- 0487US10927082B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2020·Granted Feb 23, 2021·2 cites·2 claims
- 0586US10961198B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2018·Granted Mar 30, 2021·2 cites·4 claims
- 0684US11084817B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2019·Granted Aug 10, 2021·3 cites·15 claims
- 0783US10703712B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2016·Granted Jul 7, 2020·2 cites·16 claims
- 0882US11236071B1Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2018·Granted Feb 1, 2022·2 cites·18 claims
- 0971US2022081390A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2021·Application pending·0 cites
- 1068US2021300875A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2021·Application pending·0 cites
- 1166US11214538B2Farnesoid X receptor agonists and uses thereofMETACRINE INC·Filed 2020·Granted Jan 4, 2022·0 cites·18 claims
- 1266US2022089575A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2021·Application pending·0 cites
- 1365US2022323414A1Farnesoid x receptor agonists for the treatment of diseaseMETACRINE INC·Filed 2022·Application pending·0 cites
- 1461US2022002309A1Ssao inhibitors and uses thereofMETACRINE INC·Filed 2019·Application pending·0 cites
- 1559US2020181104A1Ssao inhibitors and uses thereofMETACRINE INC·Filed 2020·Application pending·0 cites
- 1654US2022054469A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2019·Application pending·0 cites
- 1753US2023131804A1Farnesoid x receptor agonists for the treatment of diseaseMETACRINE INC·Filed 2021·Application pending·0 cites
- 1851US2022047553A1Farnesoid x receptor agonists for the treatment of diseaseMETACRINE INC·Filed 2019·Application pending·0 cites
- 1946US2022056019A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2019·Application pending·0 cites
- 2044US2021347736A1Crystalline forms of a farnesoid x receptor agonistMETACRINE INC·Filed 2019·Application pending·0 cites
- 2143US2019062277A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2016·Application pending·0 cites
- 2243US2020131132A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2018·Application pending·0 cites
- 2341US2020131129A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2018·Application pending·0 cites
- 2440US2020131142A1Farnesoid x receptor agonists and uses thereofMETACRINE INC·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →